Systematic review: Are antibiotics detrimental or beneficial for the treatment of patients with Escherichia coli O157:H7 infection?

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue 5, 2006, Pages 731-742

  Panos, G Z ^a,b   Betsi, G I ^a   Falagas, M E ^a,c,d  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b 1st IKA Hospital   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HENRY DUNANT HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFACLOR; CEFDINIR; CEFIXIME; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; FOSFOMYCIN; FURAZOLIDONE; GENTAMICIN; KANAMYCIN; LEVOFLOXACIN; MACROLIDE; METRONIDAZOLE; MINOCYCLINE; NORFLOXACIN; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROKITAMYCIN; ROXITHROMYCIN; STREPTOMYCIN; SULFAFURAZOLE; TETRACYCLINE; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG;

ANTIBIOTIC THERAPY; BLOODY DIARRHEA; CHILD SAFETY; CLINICAL TRIAL; CONCENTRATION RESPONSE; DIARRHEA; DISEASE ASSOCIATION; DOSE TIME EFFECT RELATION; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; ENTEROBACTER INFECTION; ESCHERICHIA COLI O157; GENE; HEMOLYTIC UREMIC SYNDROME; HEMORRHAGIC COLITIS; HUMAN; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; REVIEW; SLT1 GENE; SLT2 GENE; SYSTEMATIC REVIEW; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANIMALS; ANTI-BACTERIAL AGENTS; DIARRHEA; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI O157; FOSFOMYCIN; HEMOLYTIC-UREMIC SYNDROME; HUMANS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; QUINOLONES; SHIGA TOXINS; TREATMENT OUTCOME;

EID: 33747343667     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03036.x     Document Type: Review

References (63)

1. Riley LW, Remis RS, Helgerson SD, et al. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N Engl J Med 1983; 308: 681-5.
2. Tarr PI, Gordon CA, Chandler WI. Shiga-toxin-producing Escherichia coli and hemolytic uraemic syndrome. Lancet 2005; 365: 1073-86.
3. Koutkia P, Mylonakis E, Flanigan T. Enterohemorrhagic Escherichia coli O157:H7 - an emerging pathogen. American Family Physician 1997; 56: 853-67.
4. Tarr PI, Neill MA. Escherichia coli O157:H7. Gastroenterol Clin North Am 2001; 30: 735-51.
5. Safdar N, Said A, Gangnon R, et al. Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis. JAMA 2002; 288: 996-1001.
6. Acheson DW, Reidl J, Zhang X, et al. In vivo transduction with shiga toxin 1-encoding phage. Infect Immun 1998; 66: 4496-8.
7. Scotland SM, Willshaw GA, Smith HR, et al. Properties of strains of Escherichia coli belonging to subgroup O157 with special reference to production of Vero cytotoxins VT1 and VT2. Epidemiol Infect 1987; 99: 613-24.
8. O'Brien AD, Newland JW, Miller SF, et al. Shiga-like toxin-converting phages from Escherichia coli strains that cause hemorrhagic colitis or infantile diarrhea. Science 1984; 226: 694-6.
9. Takao T, Tanabe T, Hong YM, et al. Identity of molecular structure of Shiga-like toxin (VT1) from Escherichia coli O157:H7 with that of Shiga toxin. Microb Pathog 1988; 5: 57-69.
10. Waddell T, Head S, Petric M, et al. Globotriosyl ceramide is specifically recognised by the Escherichia coli verocytotoxin 2. Biochem Biophys Res Commun 1988; 152: 674-9.
11. Endo Y, Tsurugi K, Yutsudo T, et al. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem 1988; 161: 45-50.
12. Griffin PM, Ostroff SM, Tauxe RV, et al. Illnesses associated with Escherichia coli O157:H7 infections. Ann Intern Med 1988; 109: 705-12.
13. Su C, Brandt L. Escherichia coli O157:H7 infection in humans. Ann Intern Med 1995; 123: 698-707.
14. Dundas S, Todd A, Stewart A, et al. The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalised patients. Clin Infect Dis 2001; 33: 923-31.
15. Boyce TG, Swerdlow DL, Griffin PM. Escherichia coli O157:H7 and the hemolytic-uremic syndrome. N Engl J Med 1995; 333: 364-8.
16. Sack RB. Enterohemorrhagic Escherichia coli. N Engl J Med 1987; 317: 1535-7.
17. Kimmitt P, Harwood C, Barer M. Toxin gene expression by Shiga toxin-producing Escherichia coli: the role of antibiotics and the bacterial SOS response. Emerg Infect Dis 2000; 6: 458-65.
18. Pai CH, Gordon R, Sims HV, et al. Sporadic cases of hemorrhagic colitis associated with Escherichia coli O157:H7. Clinical, epidemiologic, and bacteriologic features. Ann Intern Med 1984; 101: 738-42.
19. Belongia EA, McDonald KL, Parham GL, et al. An outbreak of Escherichia coli O157:H7 colitis associated with consumption of precooked meat patties. J Infect Dis 1991; 164: 338-43.
20. Cleary TG. Cytotoxin-producing Escherichia coli and the hemolytic uremic syndrome. Pediatr Clin North Am 1988; 35: 485-501.
21. Tarr PI, Neill MA, Clausen CR, et al. Escherichia coli O157:H7 and hemolytic uremic syndrome: importance of early cultures in establishing the etiology. J Infect Dis 1990; 162: 553-6.
22. Ostroff SM, Tarr PI, Neill MA, et al. Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. J Infect Dis 1989; 160: 994-8.
23. Tarr PI, Neill MA, Christie DL, et al. Escherichia coli O157:H7 hemorrhagic colitis. N Engl J Med 1988; 318: 1697.
24. Kleanthous H, Smith HR, Scotland SM, et al. Hemolytic uraemic syndromes in the British Isles, 1985-8: association with verocytotoxin producing Escherichia coli. Part 2: microbiological aspects. Arch Dis Child 1990; 65: 722-7.
25. Roldgaard BB, Scheutz F, Boel J, et al. VTEC O157 subtypes associated with the most severe clinical symptoms in humans constitute a minor part of VTEC O157 isolates from Danish cattle. Int J Med Microbiol 2004; 294: 255-9.
26. Karmali MA, Petric M, Lim C, et al. Sensitive method for detecting low numbers of verotoxin-producing Escherichia coli in mixed cultures by use of colony sweeps and polymyxin extraction of verotoxin. J Clin Microbiol 1985; 22: 614-9.
27. Karch H, Strockbine NA, O'Brien AD. Growth of Escherichia coli in the presence of trimethoprim-sulfamethoxazole facilitates detection of Shiga-like toxin producing strains by colony blot assay. FEMS Microbiol Lett 1986; 35: 141-5.
28. Walterspiel JN, Ashkenazi S, Morrow AL, et al. Effect of subinhibitory concentrations of antibiotics on extracellular Shiga-like toxin I. Infection 1992; 20: 25-9.
29. Murakami J, Kishi K, Hirai K, et al. Macrolides and clindamycin suppress the release of Shiga-like toxins from Escherichia coli O157:H7 in vitro. Int J Antimicrob Agents 2000; 15: 103-9.
30. Yoh M, Frimpong EK, Voravuthikunchai SP, et al. Effect of subinhibitory concentrations of antimicrobial agents (quinolones and macrolide) on the production of verotoxin by enterohemorrhagic Escherichia coli O157:H7. Can J Microbiol 1999; 45: 732-9.
31. Grif K, Dierich MP, Karch H, et al. Strain-specific differences in the amount of Shiga toxin released from enterohemorrhagic Escherichia coli O157 following exposure to subinhibitory concentrations of antimicrobial agents. Eur J Clin Microbiol Infect Dis 1998; 17: 761-6.
32. Yoh M, Frimpong EK, Honda T. Effect of antimicrobial agents, especially fosfomycin, on the production and release of Vero toxin by enterohaemorrhagic Escherichia coli O157:H7. FEMS Immunol Med Microbiol 1997; 19: 57-64.
33. Yoh M, Honda T. The stimulating effect of fosfomycin, an antibiotic in common use in Japan, on the production/release of verotoxin-1 from enterohaemorrhagic Escherichia coli O157:H7 in vitro. Epidemiol Infect 1997; 119: 101-3.
34. Zhang X, McDaniel AD, Wolf LE, et al. Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J Infect Dis 2000; 181: 664-70.
35. Ito T, Akino E, Hiramatsu K. Evaluation of antibiotics used for enterohemorrhagic Escherichia coli O157 enteritis-effect of various antibiotics on extracellular release of verotoxin. Kansenshogaku Zasshi 1997; 71: 130-5.
36. Kurioka T, Yunou Y, Harada H, et al. Efficacy of antibiotic therapy for infection with Shiga-like toxin-producing Escherichia coli O157:H7 in mice with protein-calorie malnutrition. Eur J Clin Microbiol Infect Dis 1999; 18: 561-71.
37. Yoshimura K, Fujii J, Taniguchi H, et al. Chemotherapy for enterohemorrhagic Escherichia coli O157:H infection in a mouse model. FEMS Immunol Med Microbiol 1999; 26: 101-8.
38. Sawamura S, Tanaka K, Koga Y. Therapeutic effects of antibiotics against enterohemorrhagic Escherichia coli (EHEC) O157:H7 (O157) infection: in vivo analysis using germfree mice. Kansenshogaku Zasshi 1999; 73: 1054-63.
39. Butler T, Islam MR, Azad MA, et al. Risk factors for development of hemolytic uremic syndrome during shigellosis. J Pediatr 1987; 110: 894-7.
40. Kim HH, Samadpour M, Grimm L, et al. Characteristics of antibiotic-resistant Escherichia coli O157:H7 in Washington State, 1984-1991. J Infect Dis 1994; 170: 1606-9.
41. Bopp CA, Greene KD, Downes FP, et al. Unusual verotoxin-producing Escherichia coli associated with hemorrhagic colitis. J Clin Microbiol 1987; 25: 1486-9.
42. Swerdlow DL, Woodruff BA, Brady RC, et al. A waterborne outbreak in Missouri of Escherichia coli O157:H7 associated with bloody diarrhea and death. Ann Intern Med 1992; 117: 812-9.
43. Slutsker L, Ries AA, Greene KD, et al. Escherichia coli O157:H7 diarrhea in the United States: clinical and epidemiologic features. Ann Intern Med 1997; 126: 505-13.
44. Schroeder CM, Zhao C, DebRoy C, et al. Antimicrobial resistance of Escherichia coli O157 isolated from humans, cattle, swine, and food. Appl Environ Microbiol 2002; 68: 576-81.
45. Mora A, Blanco JE, Blanco M, et al. Antimicrobial resistance of Shiga toxin (verotoxin)- producing Escherichia coli O157:H7 and non-O157 strains isolated from humans, cattle, sheep, and food in Spain. Res Microbiol 2005; 156: 793-806.
46. Shiomi M, Togawa M. Sporadic cases of hemolytic uremic syndrome and hemorrhagic colitis with serum IgM antibodies to lipopolysaccharides of enterohemorrhagic Escherichia coli O157. Nippon Rinsho Japanese Journal of Clinical Medicine 1997; 55: 686-92.
47. Tsuboi I, Ida H, Yoshikawa E, et al. Antibiotic susceptibility of enterohemorrhagic Escherichia coli O157:H7 isolated from an outbreak in Japan in 1996. Antimicrobiol Agents Chemother 1998; 42: 431-2.
48. Pavia A, Nichols C, Green D, et al. Hemolytic-uremic syndrome during an outbreak of Escherichia coli O157:H7 infections in institutions for mentally retarded persons: clinical and epidemiologic observations. J Pediatr 1990; 116: 544-51.
49. Ostroff S, Kobayashi J, Lewis J. Infections with Escherichia coli O157:H7 in Washington State. The first year of statewide disease surveillance. JAMA 1989; 262: 355-9.
50. Slutsker L, Ries A, Maloney K, et al. A nationwide case-control study of Escherichia coli O157:H7 infection in the United States. J Infect Dis 1998; 177: 962-6.
51. Wong C, Jelacic S, Habeeb R, et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000; 342: 1930-6.
52. Carter AO, Borczyk AA, Carlson JA, et al. A severe outbreak of Escherichia coli O157:H7-associated hemorrhagic colitis in a nursing home. N Engl J Med 1987; 317: 1496-1500.
53. Martin DL, MacDonald KL, White KE, et al. The epidemiology and clinical aspects of the hemolytic uremic syndrome in Minnesota. N Engl J Med 1990; 323: 1161-7.
54. Cimolai N, Carter J, Morrison B, et al. Risk factors for the progression of Escherichia coli O157:H7 enteritis to hemolytic-uremic syndrome. J Pediatr 1990; 116: 589-92.
55. Higami S, Nishimoto K, Kawamura T, et al. Retrospective analysis of the relationship between HUS incidence and antibiotics among patients with Escherichia coli O157 enterocolitis in the Sakai outbreak. Kansenshogaku Zasshi 1998; 72: 266-72.
56. Shiomi M, Togawa M, Fujita K, et al. Effect of early oral fluoroquinolones in hemorrhagic colitis due to Escherichia coli O157:H7. Pediatr Intern 1999; 41: 228-32.
57. Ikeda K, Ida O, Kimoto K, et al. Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection. Clin Nephrol 1999; 52: 357-62.
58. Proulx F, Turgeon J, Delage G, et al. Randomized, controlled trial of antibiotic therapy for Escherichia coli O157:H7 enteritis. J Pediatr 1992; 121: 299-303.
59. Bell B, Griffin P, Lozano P, et al. Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. Pediatrics 1997; 100: E12.
60. Lynn RM, O'Brien SJ, Taylor CM, et al. Childhood hemolytic uremic syndrome, United Kingdom and Ireland. Emerg Infect Dis 2005; 11: 590-6.
61. Remis RS, MacDonald KL, Riley LW, et al. Sporadic cases of hemorrhagic colitis associated with Escherichia coli O157:H7. Ann Intern Med 1984; 101: 624-6.
62. Ryan CA, Tauxe RV, Hosek GW, et al. Escherichia coli O157:H7 diarrhea in a nursing home: clinical, epidemiological, and pathological findings. J Infect Dis 1986; 154: 631-8.
63. MacDonald KL, O'Leary MJ, Cohen ML, et al. Escherichia coli O157:H7, an emerging gastrointestinal pathogen. Results of a one-year, prospective, population-based study. JAMA 1988; 259: 3567-70.